ISRCTN19151731已完成未知
A blinded randomised multicentre study to evaluate fixed dose single administration filgrastim-SD/01 vs daily filgrastim as an adjuvant to chemotherapy Stage II or III/IV breast cancer
Amgen Limited (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. 18 years of age or older
- •2. Can be chemotherapy naive and/or have no more than one previous regimen of chemotherapy for metastatic disease
- •3. Blood results within acceptable range
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
1 期
A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular disease is the main reason for morbidity and increased mortality.MedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2007-001972-36-CZovartis Pharma Services AG330
进行中（未招募）
不适用
A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly - NDMedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyACROMEGALYEUCTR2007-001972-36-ITOVARTIS FARMA330
进行中（未招募）
1 期
A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.EUCTR2007-001972-36-SEovartis Pharma Services AG330
进行中（未招募）
1 期
A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegalyAcromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular disease is the main reason for morbidity and increased mortality.MedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2007-001972-36-DEovartis Pharma Services AG330
进行中（未招募）
1 期
A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.EUCTR2007-001972-36-GRovartis Pharma Services AG330